OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017: Pharmaceuticals Market Research Reports

Pharmaceuticals Market Research Reports Pharmaceuticals Market Research Reports XML feed

Increase Web Conversions Learn how marketers like you are using real-time web personalization to drive engagement and conversions. Download today! From our sponsors

OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017 Dec 30th 2013, 00:00 OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017 The acute ischemic stroke (AIS) market is poised for major changes during the forecast window out to 2017. Given the impending patent expiry of Activase/Actilyse, in 2015 and 2016 in the US and 5EU respectively, the current standard of care for AIS patients is expected to lose its leading position. From 2015 onwards, Activase is expected to see declining sales; this is not only attributed to loss of patent protection, and the subsequent erosion from potential biosimilar versions, but is largely a result of the anticipated launch of Lundbeck?s desmoteplase in 2015. This novel late-s...

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions